<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Pharm Sci</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Pharm Sci</journal-id><journal-id journal-id-type="publisher-id">IJPhS</journal-id><journal-title-group><journal-title>Indian Journal of Pharmaceutical Sciences</journal-title></journal-title-group><issn pub-type="ppub">0250-474X</issn><issn pub-type="epub">1998-3743</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26798172</article-id><article-id pub-id-type="pmc">4700710</article-id><article-id pub-id-type="publisher-id">IJPhS-77-573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates&#x02013;Fexofenadine in Taiwanese?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Y. A.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Juan</surname><given-names>C. H.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>K. Y.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1">College of Pharmacy, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan, R.O.C.</aff><aff id="aff2"><label>1</label>Protech Pharmaservices Corporation, 11F., No.3, Park St., Nangang District, Taipei City 11503, Taiwan, R.O.C.</aff><author-notes><corresp id="cor1"><label>*</label><bold>Address for correspondence</bold> E-mail: <email xlink:href="kyhsu@tmu.edu.tw">kyhsu@tmu.edu.tw</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>77</volume><issue>5</issue><fpage>573</fpage><lpage>578</lpage><history><date date-type="received"><day>07</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>02</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Pharmaceutical Sciences</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>The aim of this study was to investigate differences in organic anion transporting polypeptide 1A2 activity among the Taiwanese population via an analysis of 3 pharmacokinetic studies completed in a total of 103 healthy male Taiwanese subjects. The pharmacokinetics of fexofenadine was measured as an indicator of organic anion transporting polypeptide 1A2 activity. Using the Kolmogorov-Smirnov test and quantile plots, the frequency distributions of area under the concentration-time curve and concentration were shown to be tri-modal and to represent 3 pharmacokinetic phenotypes. In a comparison with published data, the mean area under the concentration-time curve of fexofenadine in the Taiwanese subjects was similar to that in American, German, and Indian subjects, but significantly different from that in some Asian populations, including Korean and Japanese ethnic groups. These results suggested that Taiwanese subjects showed genetic variation in fexofenadine pharmacokinetics that was associated with differences in organic anion transporting polypeptide 1A2 activity.</p></abstract><kwd-group><kwd>Fexofenadine</kwd><kwd>OATP1A2</kwd><kwd>organic anion transporting polypeptide 1A2</kwd><kwd>pharmacokinetics</kwd><kwd>Taiwanese</kwd></kwd-group></article-meta></front><body><p>Organic anion transporting polypeptide (OATP) transporters are expressed in organs and tissues that are involved in pharmacokinetics, where they mediate cellular uptake of endogenous substances, drugs, and xenobiotics[<xref rid="ref1" ref-type="bibr">1</xref>]. Thirty-nine members of the OATP superfamily have been identified in human and mammalian species; they are capable of facilitating the cellular uptake of endogenous substances, drugs, and xenobiotics in the intestine and liver, and of transporting these substances across the blood-brain barrier[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]. Among the OATP superfamily members identified in humans, OATP1A2 and OATP2B1 (encoded by <italic>SLCO1A2</italic> and <italic>SLCO2B1</italic>, respectively) are the only examples associated with drug transport in the enterocytes[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref4" ref-type="bibr">4</xref>].</p><p>Consistent with inhibition of OATP1A2 at the apical membrane of enterocytes, <italic>in vivo</italic> studies have shown that the AUC of fexofenadine decreased by approximately 25% by naringin, a low-strength OATP1A2 inhibitor, and decreased by 40&#x02013;70% by consumption of grapefruit juice or orange juice, which are strong OATP1A2 inhibitors[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>]. Similar studies were conducted using oral talinolol, in which inhibition of OATP1A2 decreased talinolol bioavailability by 44%[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>]. These studies suggest that OATP1A2 plays an important pharmacokinetic role, particularly in determining absorption capability.</p><p>Fexofenadine is a selective antihistamine that is used to relieve symptoms of allergic rhinitis, and which has fewer anticholinergic effects than other H<sub>1</sub>-antihistamines[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>]. It undergoes minimal metabolism in humans (less than 5%) and is excreted unchanged in urine and faeces after oral administration[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]. <italic>In vitro</italic> and <italic>in vivo</italic> studies have shown fexofenadine to be a substrate of OATP1A2 and OATP2B1. However, Shimizu <italic>et al</italic>. conducted <italic>in vitro</italic> tests that showed that OATP2B1 did not transport fexofenadine significantly, and that OATP1A2 was a major mediator of fexofenadine uptake[<xref rid="ref14" ref-type="bibr">14</xref>]. These properties make fexofenadine an optimal choice as a probe drug to evaluate OATP1A2 activity in humans[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>].</p><p>Some SNPs in the <italic>SLCO1A2</italic> gene have been shown to decrease OATP1A2 transport activity <italic>In vitro</italic> for substrates such as estrone-3-sulfate and imatinib[<xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>]. <italic>In vitro</italic> studies on OATP1A2 variants A516C and A404T showed markedly reduced transport of estrone-3-sulfate. Variants G559A and C2003G also appeared to possess altered transport activities[<xref rid="ref17" ref-type="bibr">17</xref>]. The effects of <italic>SLCO1A2</italic> polymorphisms on imatinib pharmacokinetics were investigated in healthy volunteers and patients, and results showed that the pharmacokinetics of imatinib were altered in patients with the 1105G&#x0003e;A/1032G&#x0003e;A and 361GG <italic>SLCO1A2</italic> genotypes[<xref rid="ref18" ref-type="bibr">18</xref>]. These findings suggest that <italic>SLCO1A2</italic> polymorphisms significantly affect the pharmacokinetics of OATP1A2 substrates such as imatinib and estrone-2-sulfate. Moreover, OATP1A2 variants were observed to be dependent on ethnic background, and such differences may result in varied AUC of OATP1A2 in particular populations[<xref rid="ref19" ref-type="bibr">19</xref>].</p><p>Based on these previously published results, fexofenadine was used as a probe drug to evaluate the function of OATP1A2 in Taiwanese subjects, and clustering methods were used to identify distinct pharmacokinetic phenotypes based on pharmacokinetic results.</p><sec sec-type="materials|methods" id="sec1-1"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Chromatographic conditions and analytical methods:</title><p>The analysis methods used in all studies reported herein were previously described by Chen <italic>et al</italic>[<xref rid="ref20" ref-type="bibr">20</xref>]. The chromatographic instrument consisted of a high-performance liquid chromatography system (1100 Series; Agilent Technologies, Wilmington, DE, USA) equipped with a tandem mass spectrometry detection system. The calibration curves for the ratio of peak area and concentration of losartan versus those of fexofenadine showed a linear relationship over a concentration range of 1&#x02013;1000 ng/ml. The mean relative error ranged from 3.0&#x02013;6.0%, and the coefficients of variance were all within acceptable ranges.</p></sec><sec id="sec2-2"><title>Subjects:</title><p>This study examined 104 healthy male Taiwanese subjects from 3 pharmacokinetic studies conducted at a single clinical facility in Taiwan, of which 103 subjects completed their respective studies. The study subjects were fasted overnight and administered a single dose of Allegra<sup>&#x000ae;</sup> (Sanofi-Aventis U.S. LLC) at a dose of 180 mg with 240 ml of water. Venous blood samples (10 ml) were drawn in heparinised tubes before dosing (0 h) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48, and 60 h after drug administration. These study protocols were approved by the Institutional Review Board of Mackay Memorial Hospital (Taipei, Taiwan) and conducted in Formotract Health Clinics (Taipei, Taiwan).</p></sec><sec id="sec2-3"><title>Data analysis:</title><p>Individual fexofenadine plasma concentration data were analysed by a non-compartmental method using the WinNonlin<sup>&#x000ae;</sup> 6.3 (Pharsight, Cary, NC) program. Pharmacokinetic parameters including the maximum observed concentration (C<sub>max</sub>), the time to peak concentration (T<sub>max</sub>), the area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC<sub>0&#x02013;t</sub>), the area under the concentration-time curve from time 0 to infinity (AUC<sub>0&#x02013;&#x0221e;</sub>), plasma half-life (t<sub>1/2</sub>), and oral clearance (CL/F) were reported. All data are expressed as mean&#x000b1;standard deviation.</p><p>To evaluate AUC and C<sub>max</sub> phenotypes and their frequencies in the Taiwanese population, the normal distribution was estimated using the Kolmogorov-Smirnov method. The quantile-quantile plots (QQ plots), agglomerative hierarchical clustering and non-hierarchical K-means clustering were used to identify each phenotype. The pharmacokinetic parameters of fexofenadine among the identified phenotypes were compared using one-way ANOVA.</p><p>An extensive literature search was performed to identify published fexofenadine pharmacokinetic studies in other populations to compare corresponding pharmacokinetic parameters. The data were collected and summarized as arithmetic means and standard deviations. In published investigations, the pharmacokinetic properties of fexofenadine were similar after administration of single and multiple doses and appeared to be dose-proportional over a range of 10&#x02013;800 mg[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>]. With respect to linear pharmacokinetics, it was reasonable to compare the data after normalizing doses.</p><p>For relief of symptoms of seasonal allergic rhinitis, the most common fexofenadine dose is 120 mg, and the most common dose for the treatment of chronic idiopathic urticaria is 180 mg. The recommended maximum daily dose of fexofenadine is 240 mg. Thus, further discussion is focused on commonly used doses of fexofenadine, which ranged from 120 mg to 240 mg[<xref rid="ref15" ref-type="bibr">15</xref>]. To minimize variation in AUC<sub>0&#x02013;t</sub>, AUCs were adjusted and recalculated based on equivalent duration. Thus, AUCs truncated to 12, 24 and 48 h values were used to compare our data with published data. The two-sample <italic>t</italic>-test was used to determine the statistical significances of difference between our data and published data.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>RESULTS</title><p>Of the 104 subjects initially enrolled, 103 subjects completed the study. One subject was withdrawn voluntarily. The mean age was 23.7&#x000b1;3.5 years, the mean body weight was 64.7&#x000b1;6.4 kg, and the mean BMI was 21.9&#x000b1;1.7 kg/m<sup>2</sup>. Nine adverse events were reported from 8 subjects. All adverse events were reported to be mild in intensity. No serious adverse events were observed.</p><p>The pharmacokinetic parameters of a single dose of 180 mg fexofenadine in 103 healthy Taiwanese volunteers are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. After oral 180 mg fexofenadine administration, the C<sub>max</sub>, AUC<sub>0&#x02013;t</sub>, AUC<sub>0&#x02013;&#x0221e;</sub>, CL/F, and t<sub>1/2</sub> were 682.49&#x000b1;301.20 ng/ml, 4323.75&#x000b1;1688.84 h&#x000d7;ng/ml, 4379.57&#x000b1;1691.94 h&#x000d7;ng/ml, 47.7&#x000b1;19.0 l/h, and 10.83&#x000b1;4.59 h, respectively. The mean ratio of AUC<sub>0&#x02013;t</sub>/AUC<sub>0&#x02013;&#x0221e;</sub> was greater than 80%, which indicated a suitable sampling schedule.</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>PHARMACOKINETICS OF FEXOFENADINE IN THREE PHENOTYPES</p></caption><graphic xlink:href="IJPhS-77-573-g001"/></table-wrap><p><xref ref-type="fig" rid="F1">Fig. 1</xref> shows quantile-quantile plots (QQ plots) with the results of the K-S tests for fexofenadine C<sub>max</sub>, AUC<sub>0&#x02013;t</sub>, and AUC<sub>0&#x02013;&#x0221e;</sub>. Based on agglomerative hierarchical clustering and non-hierarchical K-means clustering for AUC<sub>0&#x02013;t</sub>, 3 distinct phenotypes were identified and denoted as high absorption/exposure (HA), immediate absorption/exposure (IA), and poor absorption/exposure (PA), with frequencies of 15.6, 43.1, and 42.3%, respectively.</p><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Quantile plots for of fexofenadine pharmacokinetic parameters.</p><p>Quantile plots for of fexofenadine pharmacokinetic parameters in healthy Taiwanese subjects (n=103). K-S, Kolmogorov-Smirnov test. (a) C<sub>max</sub>; Mean=682.49, SD=301.20, N=103, K-S test=0.092, <italic>P</italic>-value=0.03. (b) AUC<sub>0</sub>&#x02013;<sub>t</sub>; Mean=4323.75, SD=1688.84, N=103, K-S test=0.089, <italic>P</italic>-value =0.045. (c) AUC<sub>0</sub>&#x02013;<sub>&#x0221e;</sub>; Mean=4379.57, SD=1691.94, N=103, K-S test=0.089, <italic>P</italic>-value=0.043.</p></caption><graphic xlink:href="IJPhS-77-573-g002"/></fig><p><xref ref-type="table" rid="T1">Table 1</xref> shows the mean pharmacokinetic parameters for these 3 identified phenotypes. T<sub>max</sub> and t<sub>1/2</sub> showed no significant differences among the 3 identified phenotypes. For other pharmacokinetic parameters, there were statistically significant differences between each group. The lack of change in T<sub>max</sub> and t<sub>1/2</sub> indicated that there were no differences in fexofenadine elimination rates among these 3 groups. Significant differences in CL/F among the groups indicated differences in bioavailability. These results show that polymorphisms influence fexofenadine pharmacokinetics exist in the Taiwanese population.</p><p>Studies of fexofenadine pharmacokinetics dose ranged from 120 to 240 mg have been performed in healthy American[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref23" ref-type="bibr">23</xref>], Chinese[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>], German[<xref rid="ref26" ref-type="bibr">26</xref>], Indian[<xref rid="ref27" ref-type="bibr">27</xref>], Japanese[<xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref>], and Korean[<xref rid="ref31" ref-type="bibr">31</xref>] volunteers. To minimize variation in AUC<sub>0&#x02013;t</sub>, AUCs were adjusted and recalculated based on equivalent duration. Results from the present study on the pharmacokinetic parameters of fexofenadine at these common doses were shown in <xref ref-type="table" rid="T2">Table 2</xref>. Fexofenadine AUCs in Taiwanese subjects were similar to those in American, Indian, and German subjects, but were significantly different from those in Korean and Japanese subjects.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>PHARMACOKINETIC PARAMETERS OF FEXOFENADINE IN SUBJECTS</p></caption><graphic xlink:href="IJPhS-77-573-g003"/></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title>DISCUSSION</title><p>In previous reports on OATP1A2 variation in human ethnic groups, the Chinese population was shown to possess a distinct distribution of polymorphisms, but the impact of OATP1A2 polymorphisms on fexofenadine pharmacokinetics has not been investigated[<xref rid="ref19" ref-type="bibr">19</xref>]. Therefore, this study used fexofenadine as a probe drug to determine the influence of OATP1A2 polymorphisms on pharmacokinetics. However, OATP1A2 genotyping was not performed in these studies, and thus the fexofenadine pharmacokinetic results may not provide precise pharmacokinetic information for each group.</p><p>Shon <italic>et al</italic>. reported the pharmacokinetics of fexofenadine in Korean volunteers for 24 h after administration. The value of t<sub>1/2</sub> was 5.0&#x000b1;1.7 h, which was less than that reported previously[<xref rid="ref32" ref-type="bibr">32</xref>]. Boyle <italic>et al</italic>. investigated the pharmacokinetics of fexofenadine in Japanese volunteers, but the authors suggested that a sampling time of less than 24 h was not adequate to study elimination[<xref rid="ref33" ref-type="bibr">33</xref>]. Guo <italic>et al</italic>. studied the pharmacokinetics of fexofenadine for up to 48 h and reported t<sub>1/2</sub> of 9.29&#x000b1;3.61 h after administration of 120 mg of fexofenadine. The AUC<sub>0-48</sub> and AUC<sub>0&#x02013;&#x0221e;</sub> for 120 mg of fexofenadine were 978.19&#x000b1;411.06 h&#x000d7;ng/ml. The mean ratio of AUC<sub>0-48</sub>/AUC<sub>0&#x02013;&#x0221e;</sub> was greater than 80%, which indicated a good fit with the sampling schedule[<xref rid="ref24" ref-type="bibr">24</xref>]. These data indicated that the blood sampling duration for pharmacokinetic studies of fexofenadine should be at least 48 h to capture the complete plasma-concentration profile.</p><p>Pharmacokinetic parameters such as T<sub>max</sub>, t<sub>1/2</sub> and AUC<sub>0&#x02013;&#x0221e;</sub> have been highly variable among published studies. The reasons for this variability are complex and include the sensitivity of assay methods, blood sampling schedules, and sampling duration. Thus, this study focused on AUC<sub>0&#x02013;t</sub>. Normality tests, agglomerative hierarchical clustering, and non-hierarchical K-means clustering were performed using AUC<sub>0&#x02013;t</sub> data.</p><p>Three distinct phenotypes were identified, which was an unexpected result. According to recognized OATP1A2 SNP data in the Chinese population, no variants exist in the Chinese or Han populations. However, the results of the pharmacokinetic studies showed significant differences across 3 groups. The t<sub>1/2</sub> was not changed, which indicated that the elimination rate was similar in the 3 identified phenotypes. Significant differences in CL/F indicated differences in bioavailability. These results suggested that variation in fexofenadine pharmacokinetics was attributed to differences in absorption capability, and that OATP1A2 played a key role in fexofenadine disposition.</p><p>Fexofenadine AUCs in Taiwanese subjects were similar to those in American, Indian, and German subjects, but were significantly differences from those in Korean and Japanese subjects. The fexofenadine pharmacokinetic parameters in Chinese subjects were highly variable between research reports, and thus we could not draw conclusions regarding difference between Chinese and Taiwanese populations[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>]. These results indicated that the fexofenadine AUC in the Taiwanese population were significantly different from those of other Asian populations, which was a similar result to that obtained for OATP1A2 polymorphisms. Three phenotypes were observed; however, these observations conflicted with discovered frequencies of OATP1A2 alleles, and there no SNPs were discovered in the Taiwanese population. Thus, the reasons for the observed inter-subject differences should be further investigated.</p><p>Fexofenadine is a substrate for numerous transporters in addition to OATP1A2, including OATP1B1, OATP1B3, and OATP2B1. In a report by Niemi <italic>et al</italic>. on <italic>SLCO1B1</italic> (encoding OATP1B1), the mean fexofenadine AUC in subjects with the 521CC genotype was 76.0% greater than that of subjects with the 521TC genotype, and 127% greater than that of subjects with the 521TT genotype. The <italic>SLCO1B1</italic> 521T&#x0003e;C polymorphism was shown to significantly influence the AUC, but not t<sub>1/2</sub>, of fexofenadine[<xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref>]. A similar phenomenon was observed in the present study. The AUC<sub>0&#x02013;t</sub> of the HA group was 160% greater than that of the PA group and 56% greater than that of the IA group. However, the frequency of the 521T&#x0003e;C SNP in Taiwanese subjects was 0%[<xref rid="ref36" ref-type="bibr">36</xref>]. For OATP2B1, no differences between ethnic groups were observed, and the frequencies of <italic>SCLO2B1</italic> SNPs in Taiwanese subjects were similar to their frequencies in Japanese subjects[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref>]. Thus, OATP1B1 and OATP1B3 polymorphisms may not be critical factors influencing the pharmacokinetics of fexofenadine in the Taiwanese population. Based on well-known SNPs and allele frequencies, OATP1A2 seems to be a key transporter involved in the uptake and absorption of fexofenadine in humans, and variation in OATP1A2 function seems to contribute to differences in these parameters among the Taiwanese population and other Asian populations (e.g. Korean and Japanese)[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref>].</p><p>The ethnic population-based difference in OATP1A2 was the most important finding in this research. The phenomenon was also observed on BCRP (breast cancer resistance protein). BCRP-421C&#x0003e;A is the most prevalent allele in the Asian population (40.80%) and its allele frequency is much greater than in other populations. Volunteers with BCRP genotype 421CA and 421AA exhibited greater rosuvastatin bioavailability than that in volunteers with genotype 421CC, and thus plasma levels of rosuvastatin in Asians are generally twice those observed in people of European heritage[<xref rid="ref38" ref-type="bibr">38</xref>].</p><p>The results of this study suggest that fexofenadine pharmacokinetics differ between the Taiwanese population and other Asian populations (Korean and Japanese), and are influenced by OATP1A2, which controls fexofenadine absorption in humans.</p><sec id="sec2-4"><title>Financial support and sponsorship:</title><p>Nil.</p></sec><sec id="sec2-5"><title>Conflicts of interest:</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgements:</title><p>The authors thank Protech Pharmaservices Corporation for providing all raw data for this report.</p></ack><fn-group><fn fn-type="other"><p>Chen, <italic>et al</italic>.: An Ethnic Differernce in OATP1A2 in Taiwanese</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalliokoski</surname><given-names>A</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name></person-group><article-title>Impact of OATP transporters on pharmacokinetics</article-title><source>Br J Pharmacol</source><year>2009</year><volume>158</volume><fpage>693</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">19785645</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagenbuch</surname><given-names>B</given-names></name><name><surname>Meier</surname><given-names>PJ</given-names></name></person-group><article-title>Organic anion transporting polypeptides of the OATP/ SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties</article-title><source>Pflugers Arch</source><year>2004</year><volume>447</volume><fpage>653</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">14579113</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagenbuch</surname><given-names>B</given-names></name><name><surname>Gui</surname><given-names>C</given-names></name></person-group><article-title>Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family</article-title><source>Xenobiotica</source><year>2008</year><volume>38</volume><fpage>778</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">18668430</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaeser</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>DG</given-names></name><name><surname>Dresser</surname><given-names>GK</given-names></name><name><surname>Gregor</surname><given-names>JC</given-names></name><name><surname>Schwarz</surname><given-names>UI</given-names></name><name><surname>McGrath</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Intestinal drug transporter expression and the impact of grapefruit juice in humans</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><fpage>362</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17215845</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dresser</surname><given-names>GK</given-names></name><name><surname>Bailey</surname><given-names>DG</given-names></name><name><surname>Leake</surname><given-names>BF</given-names></name><name><surname>Schwarz</surname><given-names>UI</given-names></name><name><surname>Dawson</surname><given-names>PA</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11823753</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>DG</given-names></name><name><surname>Dresser</surname><given-names>GK</given-names></name><name><surname>Leake</surname><given-names>BF</given-names></name><name><surname>Kim</surname><given-names>RB</given-names></name></person-group><article-title>Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">17301733</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>UI</given-names></name><name><surname>Seemann</surname><given-names>D</given-names></name><name><surname>Oertel</surname><given-names>R</given-names></name><name><surname>Miehlke</surname><given-names>S</given-names></name><name><surname>Kuhlisch</surname><given-names>E</given-names></name><name><surname>Fromm</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Grapefruit juice ingestion significantly reduces talinolol bioavailability</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>77</volume><fpage>291</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">15903127</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirasaka</surname><given-names>Y</given-names></name><name><surname>Kuraoka</surname><given-names>E</given-names></name><name><surname>Spahn-Langguth</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Langguth</surname><given-names>P</given-names></name><name><surname>Tamai</surname><given-names>I</given-names></name></person-group><article-title>Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat</article-title><source>J Pharmacol Exp Ther</source><year>2010</year><volume>332</volume><fpage>181</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19779132</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>A</given-names></name><name><surname>Wagstaff</surname><given-names>AJ</given-names></name></person-group><article-title>Fexofenadine</article-title><source>Drugs</source><year>1998</year><volume>55</volume><fpage>269</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">9506246</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirasaka</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Tamai</surname><given-names>I</given-names></name></person-group><article-title>Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein</article-title><source>J Pharm Sci</source><year>2011</year><volume>100</volume><fpage>3843</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21520088</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>FE</given-names></name><name><surname>Simons</surname><given-names>KJ</given-names></name></person-group><article-title>Clinical pharmacology of new histamine H1 receptor antagonists</article-title><source>Clin Pharmacokinet</source><year>1999</year><volume>36</volume><fpage>329</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">10384858</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans</article-title><source>Drugs R D</source><year>2007</year><volume>8</volume><fpage>301</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17767395</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name></person-group><article-title>Clinical pharmacokinetics of fexofenadine enantiomers</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2010</year><volume>6</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19947891</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Fuse</surname><given-names>K</given-names></name><name><surname>Okudaira</surname><given-names>K</given-names></name><name><surname>Nishigaki</surname><given-names>R</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kusuhara</surname><given-names>H</given-names></name><etal/></person-group><article-title>Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans</article-title><source>Drug Metab Dispos</source><year>2005</year><volume>33</volume><fpage>1477</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16014768</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>K</given-names></name><name><surname>Jarvis</surname><given-names>B</given-names></name></person-group><article-title>Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria</article-title><source>Drugs</source><year>2000</year><volume>59</volume><fpage>301</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10730552</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Gums</surname><given-names>JG</given-names></name></person-group><article-title>Fexofenadine: Biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2009</year><volume>5</volume><fpage>813</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19545214</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Glaeser</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>LH</given-names></name><name><surname>Roberts</surname><given-names>RL</given-names></name><name><surname>Moeckel</surname><given-names>GW</given-names></name><name><surname>Gervasini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>9610</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15632119</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamakawa</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>A</given-names></name><name><surname>Shuto</surname><given-names>T</given-names></name><name><surname>Yuki</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Kai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><fpage>157</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21633340</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;nig</surname><given-names>J</given-names></name><name><surname>Seithel</surname><given-names>A</given-names></name><name><surname>Gradhand</surname><given-names>U</given-names></name><name><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Pharmacogenomics of human OATP transporters</article-title><source>Naunyn Schmiedebergs Arch Pharmacol</source><year>2006</year><volume>372</volume><fpage>432</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16525793</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YA</given-names></name><name><surname>Chou</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>WK</given-names></name><name><surname>Hsu</surname><given-names>KY</given-names></name></person-group><article-title>Determination of fexofenadine in human plasma by LC-MS/MS and its application in pharmacokinetic study</article-title><source>J Chin Pharm Sci</source><year>2013</year><volume>22</volume><fpage>409</fpage><lpage>14</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>DK</given-names></name><name><surname>Castles</surname><given-names>MA</given-names></name><name><surname>Pack</surname><given-names>DJ</given-names></name><name><surname>Bhargava</surname><given-names>VO</given-names></name><name><surname>Weir</surname><given-names>SJ</given-names></name></person-group><article-title>Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers</article-title><source>Biopharm Drug Dispos</source><year>1998</year><volume>19</volume><fpage>455</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9818712</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>T</given-names></name><name><surname>Stoltz</surname><given-names>M</given-names></name><name><surname>Weir</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers</article-title><source>Clin Pharmacol Ther</source><year>1998</year><volume>64</volume><fpage>612</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9871426</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoltz</surname><given-names>M</given-names></name><name><surname>Arumugham</surname><given-names>T</given-names></name><name><surname>Lippert</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Bhargava</surname><given-names>V</given-names></name><name><surname>Eller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A)</article-title><source>Biopharm Drug Dispos</source><year>1997</year><volume>18</volume><fpage>645</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9330784</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name></person-group><article-title>Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: Application to a clinical pharmacokinetic study</article-title><source>Biomed Chromatogr</source><year>2010</year><volume>24</volume><fpage>335</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19629959</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Ruan</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name></person-group><article-title>Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe</article-title><source>J Ethnopharmacol</source><year>2013</year><volume>146</volume><fpage>744</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23422332</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>U</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Drescher</surname><given-names>S</given-names></name><name><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><year>2002</year><volume>766</volume><fpage>227</fpage><lpage>33</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muppavarapu</surname><given-names>R</given-names></name><name><surname>Guttikar</surname><given-names>S</given-names></name><name><surname>Rajappan</surname><given-names>M</given-names></name><name><surname>Kamarajan</surname><given-names>K</given-names></name><name><surname>Mullangi</surname><given-names>R</given-names></name></person-group><article-title>Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: Application to a bioequivalence study</article-title><source>Biomed Chromatogr</source><year>2014</year><volume>28</volume><fpage>1048</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24424850</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Yasui-Furukori</surname><given-names>N</given-names></name><name><surname>Takahata</surname><given-names>T</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>T</given-names></name></person-group><article-title>Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection</article-title><source>J Pharm Biomed Anal</source><year>2004</year><volume>35</volume><fpage>937</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15193739</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasui-Furukori</surname><given-names>N</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>T</given-names></name></person-group><article-title>Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>77</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15637527</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>T</given-names></name></person-group><article-title>Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><fpage>538</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16669847</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name></person-group><article-title>Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers</article-title><source>Eur J Clin Pharmacol</source><year>2010</year><volume>66</volume><fpage>721</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20306185</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shon</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>YR</given-names></name><name><surname>Hong</surname><given-names>WS</given-names></name><name><surname>Nguyen</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Choi</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>78</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">16084853</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Ridout</surname><given-names>F</given-names></name><name><surname>Meadows</surname><given-names>R</given-names></name><name><surname>Johnsen</surname><given-names>S</given-names></name><name><surname>Hindmarch</surname><given-names>I</given-names></name></person-group><article-title>Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>1495</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">16197669</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Kivist&#x000f6;</surname><given-names>KT</given-names></name><name><surname>Hofmann</surname><given-names>U</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Eichelbaum</surname><given-names>M</given-names></name><name><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>59</volume><fpage>602</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15842561</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Pasanen</surname><given-names>MK</given-names></name><name><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake</article-title><source>Pharmacol Rev</source><year>2011</year><volume>63</volume><fpage>157</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">21245207</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SW</given-names></name></person-group><article-title>Comparison of Antihypertensive Effect of Angiotensin II Type I Receptor Antagonists in Subjects with Genetic Polymorphism of OATP</article-title><year>2007</year><publisher-name>Thesis, National Cheng Kung University</publisher-name></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laitinen</surname><given-names>A</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name></person-group><article-title>Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2011</year><volume>108</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">20560925</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cropp</surname><given-names>CD</given-names></name><name><surname>Yee</surname><given-names>SW</given-names></name><name><surname>Giacomini</surname><given-names>KM</given-names></name></person-group><article-title>Genetic variation in drug transporters in ethnic populations</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>84</volume><fpage>412</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18528433</pub-id></element-citation></ref></ref-list></back></article>